Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125560871 | 12556087 | 1 | I | 20160705 | 20160714 | 20160714 | EXP | AU-PURDUE-USA-2016-0132066 | PURDUE | PLASEK, THOMAS M., ET. AL. SERIOUS ADVERSE DRUG REACTIONS TO ZOLPIDEM: DOES IMPAIRED METABOLIC CLEARANCE AND CONCURRENT SSRI/SNRI USE INCREASE RISK?. JOURNAL OF PHARMACY PRACTICE AND RESEARCH. 2016;46:139-142 | 30.00 | YR | F | Y | 0.00000 | 20160714 | MD | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125560871 | 12556087 | 1 | PS | ZOLPIDEM TARTRATE. | ZOLPIDEM TARTRATE | 1 | Oral | U | U | UNKNOWN | 22328 | ||||||||
| 125560871 | 12556087 | 2 | SS | ZOPICLONE | ZOPICLONE | 1 | Unknown | U | U | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125560871 | 12556087 | 1 | Insomnia |
| 125560871 | 12556087 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125560871 | 12556087 | DE |
| 125560871 | 12556087 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125560871 | 12556087 | Death | |
| 125560871 | 12556087 | Somnambulism |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |